<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02933827</url>
  </required_header>
  <id_info>
    <org_study_id>CT31</org_study_id>
    <nct_id>NCT02933827</nct_id>
  </id_info>
  <brief_title>Adipose-derived Stem Cells (ADSCs) for Moderate to Severe Chronic Kidney Disease</brief_title>
  <official_title>A Phase I/II Study to Evaluate the Safety and Efficacy of Allogeneic Infusion of Adipose-Derived Stem Cells in Moderate to Severe Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UnicoCell Biomed CO. LTD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Protech Pharmaservices Corporation (PPC)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>UnicoCell Biomed CO. LTD</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To assess the safety of allogeneic injection of expanded ADSCs to patients with Moderate
           to Severe Chronic Kidney Disease

        2. To assess the efficacy of allogeneic injection of expanded ADSCs to patients with
           Moderate to Severe Chronic Kidney Disease
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2018</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>Week 48</time_frame>
    <description>for Phase I</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline to Week 24 visit in estimated glomerular filtration rate (eGFR)</measure>
    <time_frame>Week 0, 24</time_frame>
    <description>or Phase II</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to all post-treatment visits in creatinine</measure>
    <time_frame>Weeks 0, 2, 4, 12, 24, 36, 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to all post-treatment visits in blood urea nitrogen (BUN)</measure>
    <time_frame>Weeks 2, 4, 12, 24, 36, 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to all post-treatment visits in blood cystatin C</measure>
    <time_frame>Weeks 0, 2, 4, 12, 24, 36, 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to all post-treatment visits in urine total protein-creatinine ratio (UPCR)</measure>
    <time_frame>Weeks 0, 2, 4, 12, 24, 36, 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to all post-treatment visits in plasma neutrophil gelatinase-associated lipocalin (NGAL) by enzyme-linked immunosorbent assay (ELISA)</measure>
    <time_frame>Weeks 0, 2, 4, 12, 24, 36, 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to all post-treatment visits in urine kidney injury molecule-1(KIM-1)</measure>
    <time_frame>Weeks 0, 2, 4, 12, 24, 36, 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to all post-treatment visits in urine interleukin 18 (IL-18)</measure>
    <time_frame>Weeks 2, 4, 12, 24, 36, 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to all post-treatment visits in urine liver-type fatty acid-binding protein (L-FABP)</measure>
    <time_frame>Weeks 0, 2, 4, 12, 24, 36, 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to all post-treatment visits in urine neutrophil gelatinase-associated lipocalin (NGAL)</measure>
    <time_frame>Weeks 0, 2, 4, 12, 24, 36, 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to all post-treatment visits in urine cystatin C</measure>
    <time_frame>Weeks 0, 2, 4, 12, 24, 36, 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to all post-treatment visits in hemoglobin A1c</measure>
    <time_frame>Weeks 0, 2, 4, 12, 24, 36, 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to all post-treatment visits in fasting plasma glucose</measure>
    <time_frame>Weeks 0, 2, 4, 12, 24, 36, 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with hypoglycemia (defined as blood glucose &lt; 55 mg/dL or 3.0 mmol/L) at all post-treatment visits</measure>
    <time_frame>Weeks 0, 2, 4, 12, 24, 36, 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to all post-treatment visits in body weight</measure>
    <time_frame>Weeks 0, 2, 4, 12, 24, 36, 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to all post-treatment visits in urine microalbumin-to-creatinine ratio (UMCR)</measure>
    <time_frame>Weeks 0, 2, 4, 12, 24, 36, 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to all post-treatment visits in eGFR</measure>
    <time_frame>Weeks 0, 2, 4, 12, 24, 36, 48</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Moderate to Severe Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Low dose:</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ELIXCYTE 8 mL (ADSC 6.4*10^7 cells in total)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Middle dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ELIXCYTE 24 mL (ADSC 19.2*10^7 cells in total)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ELIXCYTE 40 mL (ADSC 32.0*10^7 cells in total)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ELIXCYTE</intervention_name>
    <description>Adipose-derived stem cells (ADSCs)</description>
    <arm_group_label>High dose</arm_group_label>
    <arm_group_label>Low dose:</arm_group_label>
    <arm_group_label>Middle dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        A patient is eligible for the study if all of the followings apply:

          1. Aged 20-80 years (inclusive)

          2. With chronic kidney disease (CKD)stage 3B to 4 (eGFR 15 to 44 mL/min/1.73m2
             (inclusive)) Note : eGFR = estimated glomerular filtration rate

          3. Having provided informed consent

        Exclusion Criteria:

        Any patient meeting any of the exclusion criteria will be excluded from study
        participation.

          1. Ascertained hypersensitivity to any component used in the study Note: including
             gentamicin, DMSO, Agglutex (heperin)

          2. With inadequate hematologic function with: absolute neutrophil count (ANC) &lt;1,500/μL
             OR platelets &lt; 100,000/μL OR Hemoglobin &lt; 8 g/dL

          3. With inadequate hepatic function with: serum bilirubin, aspartate aminotransferase
             (AST), alanine aminotransferase (ALT) or alkaline phosphatase (AKP) &gt; 2.5 x the
             institutional upper limit of normal (ULN)

          4. With hemoglobin A1c (HbA1c) &gt; 8.0%

          5. With serious prior or ongoing medical conditions (e.g. concomitant illness such as
             cardiovascular (e.g. New York Heart Association grade III or IV), hepatic (e.g.
             Child-Pugh Class C), psychiatric condition, alcoholism, drug abuse), medical history,
             physical findings, ECG findings, or laboratory abnormality that in the investigators'
             opinion could interfere with the results of the trial or adversely affect the safety
             of the patient

          6. Pregnant or lactating women or premenopausal with childbearing potential but not
             taking reliable contraceptive method(s) during the study period

          7. With body mass index (BMI) greater or equal to 36 kg/m2

          8. With known history of human immunodeficiency virus (HIV) infection or any type of
             hepatitis

          9. Judged to be not applicable to this study by investigator such as difficulty of
             follow-up observation

         10. With any other serious diseases/medical history considered by the investigator not in
             the condition to enter the trial

         11. Having participated other investigational study within 4 weeks of entering this study

         12. Known or suspected abuse of alcohol or narcotics

         13. With known history of cancer within past 5 years

         14. With any autoimmune disease

         15. With cystic kidney disease or requiring kidney dialysis

         16. With precancerous condition or with cancer within past 5 years before Screening visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mai-Szu Wu, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taipei Medical University Shuang Ho Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eva Chen</last_name>
    <phone>+886-2-2791-1826</phone>
    <phone_ext>158</phone_ext>
    <email>eva@unicocell.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Taipei Medical University Shuang Ho Hospital</name>
      <address>
        <city>New Taipei City</city>
        <zip>235</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mai-Szu Wu, PhD</last_name>
      <email>maiszuwu@s.tmu.edu.tw</email>
    </contact>
    <investigator>
      <last_name>Mai-Szu Wu, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital Linkou</name>
      <address>
        <city>Taoyuan City</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ya-Chung Tian, PhD</last_name>
      <phone>886-3-328-1200</phone>
      <phone_ext>8181</phone_ext>
      <email>dryctian@cgmh.org.tw</email>
    </contact>
    <investigator>
      <last_name>Ya-Chung Tian, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>October 13, 2016</study_first_submitted>
  <study_first_submitted_qc>October 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2016</study_first_posted>
  <last_update_submitted>September 23, 2019</last_update_submitted>
  <last_update_submitted_qc>September 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

